Building on its recent efforts to reverse the US epidemic of opioid abuse, the FDA has issued draft guidance for the pharmaceutical industry to develop generic abuse-deterrent formulations of approved opioid medications.
Last year, the FDA provided the industry with final guidance on developing abuse-deterrent versions of brand-name opioids. “We recognize that abuse-deterrent technology is still evolving and is only 1 piece of a much broader strategy to combat the problem of opioid abuse,” FDA Commissioner Robert Califf, MD, said in a statement (http://1.usa.gov/25nA0QN).
Voelker R. New Salvo Against Opioid Abuse. JAMA. 2016;315(17):1826. doi:10.1001/jama.2016.4409